Results 221 to 230 of about 150,306 (248)

Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9543-9551, October 2026.
ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu, Chengsheng Ju, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Scottish Diabetes Research Network Epidemiology Group, Peter Hanlon, Robert Lindsay, David McAllister, John Petrie, Naveed Sattar, Brian Kennon, Sam Philip, Scott Cunningham, Huan Wang, William Berthon, Helen Colhoun, Paul McKeigue, Sarah Wild, Ewan R. Pearson, Li Wei, Ruth Andrew   +20 more
wiley   +1 more source

Association between serum uric acid and benign prostatic hyperplasia among Chinese men aged 45 years or older: A prospective cohort study. [PDF]

Medicine (Baltimore)
Li J, Cao P, Chen Y.
europepmc   +1 more source

Tracking outcome changes in benign prostatic hyperplasia trials: a version history review of ClinicalTrials.gov records. [PDF]

Trials
Livsey T, Itani M, Elghzali A, Hazlitt R, Keefer K, Sherry R, Archer D, Ford AI, Vassar M.   +8 more
europepmc   +1 more source

Correction to 'Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial'. [PDF]

BJU Int
europepmc   +1 more source

Aquablation/AquaBeam Waterjet Therapy for Benign Prostatic Hyperplasia: Three-Year Functional and Ejaculatory Outcomes in a Multicenter Real-World Italian Cohort. [PDF]

Low Urin Tract Symptoms
Porreca A, D'Agostino D, De Marchi D, Giampaoli M, Marino F, Busetto GM, Amodeo A, Corsi P, Claps F, Di Gianfrancesco L.   +9 more
europepmc   +1 more source

A Mixed-Methods Panel on the Uptake of New Medical Technologies for Benign Prostatic Hyperplasia in the United Arab Emirates. [PDF]

Cureus
Ahmed K, Abdul-Rahman A, Mohammed YJ, Al-Qudah H, Bagheri F, Alrawi M, Alhasani S, Alkasab T, Bosworth Smith A, Seemann K, Saunders R, Woodward E, Farahat Y.   +12 more
europepmc   +1 more source

Epidemiology of clinical benign prostatic hyperplasia

Asian Journal of Urology, 2017
Clinical benign prostatic hyperplasia (BPH) is one of the most common diseases in ageing men and the most common cause of lower urinary tract symptoms (LUTS).
Kok Bin Lim
exaly   +2 more sources